StockNews.com began coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX – Free Report) in a report released on Friday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.
Eagle Pharmaceuticals Trading Up 22.5 %
EGRX opened at $0.98 on Friday. Eagle Pharmaceuticals has a 1-year low of $0.00 and a 1-year high of $6.81. The firm’s 50 day simple moving average is $0.68 and its two-hundred day simple moving average is $2.35.
Hedge Funds Weigh In On Eagle Pharmaceuticals
Several hedge funds have recently bought and sold shares of EGRX. Perceptive Advisors LLC purchased a new stake in Eagle Pharmaceuticals during the second quarter worth $971,000. RBF Capital LLC boosted its position in shares of Eagle Pharmaceuticals by 11.7% during the 3rd quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock worth $534,000 after purchasing an additional 14,991 shares during the period. Jacobs Levy Equity Management Inc. purchased a new stake in Eagle Pharmaceuticals during the 3rd quarter worth approximately $453,000. DGS Capital Management LLC raised its holdings in Eagle Pharmaceuticals by 44.9% in the third quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock valued at $268,000 after acquiring an additional 22,239 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in Eagle Pharmaceuticals during the third quarter worth approximately $96,000. Institutional investors own 85.36% of the company’s stock.
About Eagle Pharmaceuticals
Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.
Featured Stories
- Five stocks we like better than Eagle Pharmaceuticals
- Overbought Stocks Explained: Should You Trade Them?
- MP Materials: Rare Earth Elements Powering the EV Boom
- What Are Dividend Challengers?
- Verizon’s Turnaround Gains Traction: New Highs Are Likely in 2025
- Most Volatile Stocks, What Investors Need to Know
- Bloom Energy: Powering the Future With Decentralized Energy
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
